NVS•benzinga•
Reported Earlier, Novartis Gains FDA Accelerated Approval For Vanrafia, The First Selective ETA Receptor Antagonist For Proteinuria Reduction In IgA Nephropathy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 3, 2025 by benzinga